Murine Anti-ADAMTS13

Clone GMA-360

ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 repeat, member 13) is also known as von Willebrand factor-cleaving protease (VWFCP). It is a 195 kDa plasma glycoprotein that cleaves the Tyr1605-Met1606 bond in the A2 domain of von Willebrand factor. IgG autoantibodies against ADAMTS13 are a primary cause of the potentially fatal syndrome thrombotic thrombocytopenic purpura (TTP). GMA-360 binds the disintegrin domain of ADAMTS13 and is suitable for affinity purification, immunostaining in cells, Western blot, and ELISA.

Description

Antibody Source:	mouse monoclonal, IgG_1
Antigen Species Bound:	human
Specificity:	disintegrin domain of ADAMTS13
Immunogen:	disintegrin domain of ADAMTS13

Formulation and Storage

Purity:	Purified by protein G affinity chromatography from serum-free cell culture supernatant.
Product Formulation:	Lyophilized from a ≥1 mg/ml solution in 20 mM NaH_2PO_4 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 ($\varepsilon_{0.1\%}$).
Reconstitution:	Reconstitute with deionized water.
Storage:	Store lyophilized or reconstituted and aliquoted material at -20°C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4°C.
Country of Origin:	USA
Size Options:	0.1 mg or 0.5 mg

Applications

Working Concentration:	Approximately 1-5 µg/ml. Researcher should titer antibody in specific assay.
ELISA:	Binds the disintegrin domain of ADAMTS13.
Immunoblotting:	Binds the disintegrin domain of ADAMTS13.



References

[1] D. Li, J. Xiao, M. Paessler, X. L. Zheng. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. (2011). *Thromb Haemostasis*. 106(5):947-958.

[2] C. Jian, J. Xiao, L. Gong, C. G. Skipwith, S.-Y. JIn, H. C. Kwaan, X. L. Zheng. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. (2012). *Blood*. 119(16):3836-3843.

[3] M. S. Abdelgawwad, W. Cao, L. Zheng, N. K. Kocher, L. A. Williams, X. L. Zheng. Transfusion of platelets loaded with recombinant ADAMTS13 is efficacious for inhibiting arterial thrombosis in mice and in human. (2018). *Arterioscler Thromb Vasc Biol.* 38(11):2731–2743.

[4] Q. Ma, P. M. Jacobi, B. T. Emmer, C. A. Kretz, A. B. Ozel, B. McGee, C. Kimchi-Sarfaty, D.Ginsburg, J. Z. Li, K. C. Desch. Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. (2017). *Blood Advances.* 1(15):1037-1046.